Lightlake Therapeutics has announced that it has begun a new trial of its intranasal naloxone for the reversal of opioid overdose. According to the company, it plans to file a New Drug Application with the FDA if the results from this study are positive.
Earlier this year, Lightlake announced that it had received funding for the study from the National Institute on Drug Abuse (NIDA) and that it filed an IND for the product. The company also announced that it has already signed a manufacturing contract.
Lightlake CEO Roger Crystal said, “This trial will build on the previous successful trial conducted in collaboration with NIDA last year. We have now optimized our formulation and device, and look forward to the clinical results that will bring us closer to launching a critically needed commercial product that can save lives.”
Read the Lightlake press release.
